SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Xenpozyme

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval August 2022, EMA June 2022, Japan March 2022).
Why 3/10
Xenpozyme is already approved and marketed with no pending regulatory decision or pivotal readout. It is a very small part of Sanofi's diversified portfolio (EUR 38 million in 2024 sales vs. Sanofi's EUR 46.7 billion total 2025 revenue). Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5, and the minimal concentration at Sanofi places it at the low end.
Actionable Insight NEUTRAL

Xenpozyme is already approved and commercializing with no pending regulatory decisions or pivotal readouts. The next catalyst to watch would be Sanofi's full-year 2026 earnings (expected early February 2027) for Xenpozyme's annual sales growth trajectory. For a diversified giant like Sanofi, Xenpozyme's performance is unlikely to be a material stock-moving event on its own.

Price Chart

Loading chart...

Executive Summary

Xenpozyme (olipudase alfa) is Sanofi's enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease types A/B and B), an ultra-rare genetic disorder affecting fewer than 120 people in the U.S. It was first approved globally in Japan (March 2022), then by the FDA (August 2022) and EMA (June 2022) as the first and only disease-specific treatment for non-CNS manifestations of ASMD in adult and pediatric patients. A pediatric label expansion (sBLA) was approved in 2024. Xenpozyme generated EUR 38 million in 2024 sales (up 50% YoY), but is a very small component of Sanofi's overall portfolio (Sanofi Q3 2026 sales were EUR 14.4 billion). No near-term binary catalysts exist for this drug.

How It Works

Xenpozyme is an enzyme replacement therapy. Patients with ASMD are born with a genetic defect that prevents their bodies from producing a working version of an enzyme called acid sphingomyelinase (ASM). Without this enzyme, a fatty substance called sphingomyelin builds up in cells, damaging organs like the lungs, liver, and spleen. Xenpozyme is a lab-made version of the missing enzyme, delivered intravenously (by IV infusion) every two weeks, that breaks down the accumulated fatty material.

Trial Status

Xenpozyme was approved based on the Phase 2/3 ASCEND trial (placebo-controlled in 31 adults) and the ASCEND-Peds open-label trial (8 pediatric patients). Both showed improvements in lung function (DLco) and reductions in spleen and liver volumes. A Phase 2 extension study in France (NCT06949358) completed in April 2025. The FDA approved a pediatric label expansion via sBLA in 2024.

The Two-Sided Case

▲ Bull Case4
Xenpozyme is the first and only approved treatment for ASMD, giving it a monopoly position in an ultra-rare disease with no direct competition.
Sales grew 50% year-over-year to EUR 38 million in 2024, driven by increased patient identification and geographic expansion.
Patent protection extends to approximately March 2035, providing a long exclusivity runway.
The drug is approved in the U.S., EU, and Japan, with ongoing geographic expansion (e.g., China launches noted in Q3 2026).
▼ Bear Case4
ASMD affects fewer than 120 patients in the U.S., capping the addressable market and revenue potential at a small fraction of Sanofi's total sales.
Xenpozyme is a tiny component of Sanofi's EUR 46.7 billion+ annual revenue, so even strong growth has negligible impact on Sanofi's stock price.
The drug carries a Boxed Warning for anaphylaxis risk, and infusion-related reactions are common.
As a biologic enzyme replacement therapy requiring IV infusion every two weeks, it faces inherent treatment burden and compliance challenges.

Upcoming Catalysts

  • No near-term binary catalysts for Xenpozyme specifically. The drug is already approved and commercializing. Sanofi's full-year 2026 earnings (expected early February 2027) will include Xenpozyme's annual sales figures.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 9

Hover a chip for the title
1 sanofi.com2 en.wikipedia.org3 biopharmadive.com4 accessdata.fda.gov5 sanofi.com6 sanofi.com7 cliffbio.com8 drugs.com9 sanofi.com